Novel 2,3 ‑disubstituted 1,3‑thiazolidin‑4‑one derivatives as potential antitumor agents in renal cell adenocarcinoma.
Novel 2,3‑disubstituted 1,3‑thiazolidin‑4‑one derivatives as potential antitumor agents in renal cell adenocarcinoma.
Oncol Rep. 2018 Oct 16;:
Authors: Gawrońska-Grzywacz M, Popiołek Ł, Natorska-Chomicka D, Piątkowska-Chmiel I, Izdebska M, Herbet M, Iwan M, Korga A, Dudka J, Wujec M
Abstract
Cancer represents one of the main causes of mortality in developed countries. In particular, the overall survival of patients with renal cell carcinoma (RCC) remains poor and the available cytostatic agents are insufficient. Therefore, there is an urgent requirement to identify more effective and safer anticancer drugs. Recently, the evaluation of antitumor activity appeared to be promising for thiazolidinone derivatives. The present study presents the synthesis and the cytotoxicity assays of 1,3‑thiazolidin‑4‑ones. The newly synthesized substances were screened in vitro against selected cancer human renal cell adenocarcinoma cells (769‑P), human hepatoblastoma‑derived cells (HepG2) and normal green monkey kidney cells (GMK) as a reference cell line. N‑[2‑(4‑methylphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl]acetamide and N‑[2‑(4‑methylphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl]benzamide displayed significant antiproliferative activity towards 769‑P. To elucidate the mechanisms of the cytotoxic actions, additional studies on the cell cycle and apoptosis were performed. The aforementioned compounds were ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Hepatoblastoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology